Plotka, A.
636  results:
Search for persons X
?
1

Immunosenescence and Alzheimer's Disease:

, In: Healthy Ageing and Longevity; Healthy Longevity and Immune System,
Fulop, T. ; Larbi, A. ; Khalil, A.... - p. 177-199 , 2021
 
?
2

315 Impact of acid-reducing agents (ARAS) on the pharmacoki..:

Sun, W. ; Klamerus, K.J. ; Yuhas, L.M....
European Journal of Cancer.  51 (2015)  - p. S59-S60 , 2015
 
?
4

Concomitant blockade of 5-HT1A receptor and 5-HT transporte..:

Parks, V. ; Philipp, A.W. ; Raje, S....
European Neuropsychopharmacology.  22 (2012)  2 - p. 92-99 , 2012
 
?
5

P.1.c.039 Concomitant blockade of 5-HT1a receptor and 5-HT ..:

Parks, V. ; Chalon, S. ; Raje, S....
European Neuropsychopharmacology.  18 (2008)  - p. S241-S242 , 2008
 
?
6

A Positron Emission Tomography Study to Assess Binding of L..:

Raje, S ; Patat, A A ; Parks, V...
Clinical Pharmacology & Therapeutics.  83 (2007)  1 - p. 86-96 , 2007
 
?
7

PIII-39Safety, tolerability and pharmacokinetics (PK) of mu..:

PARKS, V ; RAJE, S ; PATAT, A...
Clinical Pharmacology & Therapeutics.  79 (2006)  2 - p. P68-P68 , 2006
 
?
8

PI-34Use of positron emission tomography (PET) to assist in..:

PATAT, A ; RAJE, S ; LANGSTROM, B...
Clinical Pharmacology & Therapeutics.  79 (2006)  2 - p. P16-P16 , 2006
 
?
9

PI-68Bioavailability and pharmacokinetics of desvenlafaxine..:

RICHARDS, L ; PLOTKA, A ; BEHRLE, J..
Clinical Pharmacology & Therapeutics.  79 (2006)  2 - p. P25-P25 , 2006
 
?
10

PII-33Relative bioavailability of three modified release fo..:

RAJE, S ; PARKS, V ; PLOTKA, A..
Clinical Pharmacology & Therapeutics.  79 (2006)  2 - p. P45-P45 , 2006
 
?
11

Age-gender study of SRA-333, a novel 5-HT antagonist:

PATAT, A ; PARKS, V ; RAJE, S..
Clinical Pharmacology & Therapeutics.  77 (2005)  2 - p. P29-P29 , 2005
 
1-15